Grünenthal and Akashi ink deal on HT-100 Duchenne muscular dystrophy candidate

9 January 2016

Family-owned German drugmaker Grünenthal on Friday announced the joint global drug development program with USA-based Akashi Therapeutics for HT-100, an orally available small molecule drug candidate designed to reduce fibrosis and inflammation and to promote healthy muscle fiber regeneration in Duchenne Muscular Dystrophy (DMD) patients.

The drug has orphan designation in both the USA and the European Union, and fast track designation in the USA. Grünenthal will be responsible for commercialization in Europe and Latin America, while Akashi Therapeutics will retain rights for the USA and all other markets. This partnership is a key milestone in Grünenthal’s strategy to broaden its portfolio in niche indications by building on its track record of bringing innovative pain therapies to patients.

Grunenthal to commit $100 million to the partnership

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK